Lb Pharmaceuticals (LBRX) Cash from Investing Activities (2024 - 2026)

Lb Pharmaceuticals' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$32000.0 for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 100.64% year-over-year to -$32000.0 in Q1 2026; TTM through Mar 2026 was $18.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$39.9 million, down 271.68% from the prior year.
• Cash from Investing Activities advanced to -$32000.0 in Q1 2026 per LBRX's latest filing, from -$40000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $13.5 million in Q4 2024 and bottomed at -$40000.0 in Q4 2025.
• The 3-year median for Cash from Investing Activities is $2.5 million (2025), against an average of $4.6 million.
• Across the five-year window, Cash from Investing Activities plunged 100.3% in 2025 and slumped 100.64% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at $13.5 million in 2024, then slumped by 100.3% to -$40000.0 in 2025, then gained by 20.0% to -$32000.0 in 2026.
• Per Business Quant, the three latest LBRX Cash from Investing Activities figures stand at -$32000.0 (Q1 2026), -$40000.0 (Q4 2025), and $5.0 million (Q1 2025).